Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:GlcCer 18:1;O2/18:0)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004163 AN006911 Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function Cultured cells Human Metabolic disease Denali Therapeutics LC-MS
ST004163 AN006911 Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function Cultured cells Human Parkinsons disease Denali Therapeutics LC-MS
ST004162 AN006907 Targeted Lipid Profiling of Mouse Brains with GBA1 E326K Loss-of-Function Brain Mouse Metabolic disease Denali Therapeutics LC-MS
ST004162 AN006907 Targeted Lipid Profiling of Mouse Brains with GBA1 E326K Loss-of-Function Brain Mouse Parkinsons disease Denali Therapeutics LC-MS
ST004093 AN006783 Autoimmune Disease Risk Gene ANKRD55 Promotes T Cell Proliferation and Th17 2 Effector Function Through Metabolic Modulation T-cells Mouse Autoimmune disease Broad Institute of MIT and Harvard LC-MS
ST004059 AN006718 Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice Brain Mouse Neurodegenerative disease Denali Therapeutics LC-MS
ST004059 AN006718 Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice Brain Mouse Parkinsons disease Denali Therapeutics LC-MS
ST004058 AN006709 Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells Cultured cells Human Neurodegenerative disease Denali Therapeutics LC-MS
ST004058 AN006709 Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells Cultured cells Human Parkinsons disease Denali Therapeutics LC-MS
ST003805 AN006254 Epigenetic changes, neuronal dysregulation and behavioral abnormalities in Zmym2+/- mutant mice, a genetic animal model of schizophrenia and neurodevelopmental disorders Brain Mouse Neurodevelopment Disorder Broad Institute of MIT and Harvard LC-MS
ST003805 AN006254 Epigenetic changes, neuronal dysregulation and behavioral abnormalities in Zmym2+/- mutant mice, a genetic animal model of schizophrenia and neurodevelopmental disorders Brain Mouse Schizophrenia Broad Institute of MIT and Harvard LC-MS
ST003788 AN006443 Pre-treatment untargeted cerebrospinal fluid metabolomic profiling in tuberculous meningitis reveals multiple pathways associated with mortality Cerebrospinal fluid Human Meningitis Broad Institute of MIT and Harvard LC-MS
ST003788 AN006443 Pre-treatment untargeted cerebrospinal fluid metabolomic profiling in tuberculous meningitis reveals multiple pathways associated with mortality Cerebrospinal fluid Human Tuberculosis Broad Institute of MIT and Harvard LC-MS
ST003438 AN005649 Unbiased genetic screening and metabolomics identifies glial adenosine metabolism as a therapeutic target in Parkinson’s disease Fly Head Fruit fly Parkinsons disease Broad Institute of MIT and Harvard LC-MS
ST003215 AN005272 Protein restriction slows the development and progression of Alzheimer's disease in mice Brain Mouse Alzheimers disease University of Wisconsin-Madison LC-MS
ST001289 AN002142 Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses Macrophages Mouse LIPID MAPS GC-MS/LC-MS
ST001286 AN002137 Lipid composition of isolated lipid droplets from the functional bovine corpus luteum Ovaries Cow University of Nebraska Medical Center LC-MS
ST001140 AN001871 Changes in the Canine Plasma Lipidome after Short- and Long-Term Excess Glucocorticoid Exposure Blood Dog National University of Singapore;University of Zurich LC-MS
ST001059 AN001733 Lipidomics for wildlife disease etiology and biomarker discovery: a case study of pansteatitis outbreak in South Africa (part-II) Adipose tissue Mozambique tilapia Inflammation South East Center for Integrated Metabolomics LC-MS
ST000917 AN001501 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine Urine Human Fatty liver disease LIPID MAPS GC-MS/LC-MS
ST000916 AN001495 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma Blood Human Fatty liver disease LIPID MAPS GC-MS/LC-MS
ST000915 AN001489 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver Liver Human Fatty liver disease LIPID MAPS GC-MS/LC-MS
ST000242 AN000377 Whole unconditioned medium (Defined culture media, M199),Whole M1 medium,Whole M2 medium Macrophages Human Mayo Clinic LC-MS
ST000005 AN000012 Timecourse on RAW 264.7 cells treated with Kdo2-Lipid A and compactin Macrophages Mouse LIPID MAPS GC-MS/LC-MS
  logo